Trial Profile

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs XmAb 819 (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; First in man
Sponsors Xencor

Most Recent Events

06 Aug 2025 According to a Xencor media release, company plans to present initial dose-escalation data at a medical conference during the fourth quarter of 2025.
06 Aug 2025 According to a Xencor media release, company is on-track to present preliminary safety and efficacy from XmAb819 in advanced clear cell renal cell carcinoma later this year
31 Jul 2025 Planned End Date changed from 1 Mar 2027 to 1 Nov 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com